NCT03211065View on ClinicalTrials.gov

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2019

Conditions
Secondary Immune Deficiency
Interventions
DRUG

20% subcutaneous immunoglobulin

Subcutaneous Immunoglobulin

Trial Locations (1)

14607

Allergy and Immunology, 222 Alexander Street, Rochester

All Listed Sponsors
lead

Rochester General Hospital

OTHER

NCT03211065 - Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig | Biotech Hunter | Biotech Hunter